Inventor · disambiguated record
Jochen Probst
Also filed as: PROBST JOCHEN
37 granted patents·34 pending applications·1,134 citations·filing 2007–2025
98Inventor score
Top patents by PatentIndex Score
71 records- 0199US10434158B2Combination of vaccination and inhibition of the PD-1 pathwayCUREVAC AG·Filed 2018·Granted Oct 8, 2019·31 cites·21 claims
- 0299US10117920B2Combination of vaccination and inhibition of the PD-1 pathwayCUREVAC AG·Filed 2018·Granted Nov 6, 2018·32 cites·12 claims
- 0398US11458195B2Combination of vaccination and inhibition of the PD-1 pathwayCUREVAC AG·Filed 2019·Granted Oct 4, 2022·12 cites·25 claims
- 0498US11110156B2Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigenCUREVAC AG·Filed 2018·Granted Sep 7, 2021·28 cites·18 claims
- 0598US10912826B2Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigenCUREVAC AG·Filed 2020·Granted Feb 9, 2021·45 cites·21 claims
- 0698US10898589B2Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic proteinCUREVAC AG·Filed 2018·Granted Jan 26, 2021·28 cites·16 claims
- 0798US10799577B2Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigenCUREVAC AG·Filed 2018·Granted Oct 13, 2020·28 cites·22 claims
- 0898US10682406B2Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigenCUREVAC AG·Filed 2018·Granted Jun 16, 2020·29 cites·22 claims
- 0998US10293058B2RNA containing composition for treatment of tumor diseasesCUREVAC AG·Filed 2016·Granted May 21, 2019·50 cites·16 claims
- 1098US10166283B2Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigenCUREVAC AG·Filed 2017·Granted Jan 1, 2019·37 cites·19 claims
- 1198US10111968B2Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic proteinCUREVAC AG·Filed 2016·Granted Oct 30, 2018·39 cites·20 claims
- 1298US9839697B2Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded proteinCUREVAC AG·Filed 2015·Granted Dec 12, 2017·39 cites·20 claims
- 1398US9669089B2Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigenCUREVAC GMBH·Filed 2013·Granted Jun 6, 2017·107 cites·21 claims
- 1498US9447431B2Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic proteinCUREVAC GMBH·Filed 2013·Granted Sep 20, 2016·70 cites·16 claims
- 1597US11661634B2Method for producing RNACUREVAC MFG GMBH·Filed 2022·Granted May 30, 2023·7 cites·30 claims
- 1697US11268157B2Method for producing RNACUREVAC REAL ESTATE GMBH·Filed 2020·Granted Mar 8, 2022·29 cites·18 claims
- 1797US10918740B2RNA containing composition for treatment of tumor diseasesCUREVAC AG·Filed 2018·Granted Feb 16, 2021·38 cites·19 claims
- 1897US10711315B2Method for producing RNACUREVAC REAL ESTATE GMBH·Filed 2018·Granted Jul 14, 2020·28 cites·16 claims
- 1997US10653799B2Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded proteinCUREVAC AG·Filed 2017·Granted May 19, 2020·28 cites·20 claims
- 2097US10610605B2Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic proteinCUREVAC AG·Filed 2018·Granted Apr 7, 2020·28 cites·17 claims
- 2197US10232024B2Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigenCUREVAC AG·Filed 2013·Granted Mar 19, 2019·32 cites·15 claims
- 2297US9974845B2Combination of vaccination and inhibition of the PD-1 pathwayCUREVAC AG·Filed 2014·Granted May 22, 2018·32 cites·10 claims
- 2396US10869935B2RNA containing composition for treatment of tumor diseasesCUREVAC AG·Filed 2019·Granted Dec 22, 2020·29 cites·23 claims
- 2496US10434154B2Composition for treating prostate cancer (PCa)CUREVAC AG·Filed 2016·Granted Oct 8, 2019·29 cites·15 claims
- 2596US10017826B2Method for producing RNACUREVAC AG·Filed 2016·Granted Jul 10, 2018·29 cites·34 claims
- 2696US10010592B2Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigenCUREVAC AG·Filed 2013·Granted Jul 3, 2018·36 cites·15 claims
- 2795US11559570B2Prime-boost regimens involving administration of at least one mRNA constructCureVac SE·Filed 2016·Granted Jan 24, 2023·8 cites·22 claims
- 2895US9402887B2Composition for treating prostate cancer (PCa)CUREVAC AG·Filed 2013·Granted Aug 2, 2016·30 cites·48 claims
- 2995US9234013B2Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded proteinTHESS ANDREAS·Filed 2011·Granted Jan 12, 2016·44 cites·19 claims
- 3094US9352028B2Composition for treating lung cancer, particularly of non-small lung cancers (NSCLC)CUREVAC GMBH·Filed 2013·Granted May 31, 2016·33 cites·67 claims
- 3194US9226959B2Nucleic acids comprising formula (NuGlXmGnNv)a and derivatives thereof as immunostimulating agent/adjuvantKRAMPS THOMAS·Filed 2009·Granted Jan 5, 2016·57 cites·34 claims
- 3293US11421038B2RNA-coded antibodyHOERR INGMAR·Filed 2008·Granted Aug 23, 2022·12 cites·31 claims
- 3392US10441653B2Nucleic acid comprising GlXmGn as an immune-stimulating agent/adjuvantHOERR INGMAR·Filed 2012·Granted Oct 15, 2019·29 cites·33 claims
- 3492US2025352636A1Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigenCureVac SE·Filed 2024·Application pending·0 cites
- 3587US2025152745A1Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded proteinCureVac SE·Filed 2024·Application pending·0 cites
- 3686US12109275B2Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded proteinCureVac SE·Filed 2020·Granted Oct 8, 2024·1 cites·19 claims
- 3785US2022372158A1Rna-coded antibodyCUREVAC AG·Filed 2022·Application pending·0 cites
- 3884US12447209B2Combination of vaccination and inhibition of the PD-1 pathwayCureVac SE·Filed 2022·Granted Oct 21, 2025·0 cites·35 claims
- 3981US2025213724A1Rna containing composition for treatment of tumor diseasesCureVac SE·Filed 2025·Application pending·0 cites
- 4081US2023338579A1Rna containing composition for treatment of tumor diseasesCureVac SE·Filed 2022·Application pending·0 cites
- 4179US2022154253A1Method for producing rnaCUREVAC REAL ESTATE GMBH·Filed 2022·Application pending·0 cites
- 4278US12201680B2Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigenCureVac SE·Filed 2020·Granted Jan 21, 2025·0 cites·23 claims
- 4376US12048738B2Composition for treating prostate cancer (PCa)CureVac SE·Filed 2019·Granted Jul 30, 2024·0 cites·18 claims
- 4476US2022401555A1NUCLEIC ACIDS COMPRISING FORMULA (NuGlXmGnNv)a AND DERIVATIVES THEREOF AS IMMUNOSTIMULATING AGENT/ADJUVANTCUREVAC AG·Filed 2022·Application pending·0 cites
- 4574US2021060181A1Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic proteinCUREVAC AG·Filed 2020·Application pending·0 cites
- 4674US2022096616A1Composition for treating lung cancer, particularly of non-small lung cancers (nsclc)CUREVAC AG·Filed 2021·Application pending·0 cites
- 4773US2019284260A1Rna-coded antibodyCUREVAC AG·Filed 2019·Application pending·0 cites
- 4872US2023210965A1PRIME-BOOST REGIMENS INVOLVING ADMINISTRATION OF AT LEAST ONE mRNA CONSTRUCTCureVac SE·Filed 2022·Application pending·0 cites
- 4971US2010291156A1Composition for treating lung cancer, particularly of non-small lung cancers (nsclc)BARNER MARIJKE·Filed 2008·Application pending·0 cites
- 5070US2021393755A1Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigenCUREVAC AG·Filed 2021·Application pending·0 cites
Showing the top 50 of 71 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Jochen Probst files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →